en · de · es · fr · pt
sr9009-notes.peptides3626.com › News › Background And Receptor Pharmacology — What the Evidence Shows

Background And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2025-12-19 · last reviewed 2026-01-30 · News

This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Related pages on this site

Reference notes

== Medical uses == Thiotepa is used in combination with other chemotherapy agents to treat cancer. It can be given with or without total body irradiation (TBI) to prepare the body for allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT), which replaces damaged blood-forming cells with donor cells. This treatment is used in both adults and children for blood cancers such as Hodgkin lymphoma and leukemia. Thiotepa is also used with high-dose chemotherapy and HPCT support to treat certain solid tumors in adults and children. Thiotepa is used in palliative care for several types of cancer, including breast cancer, ovarian cancer, papillary thyroid cancer, and bladder cancer. It is also used to control intracavitary effusions caused by serosal neoplastic deposits, which refers to fluid buildup resulting from cancer spreading to the lining of body cavities. In Japan, a widely used regimen consisting of high-dose thiotepa and melphalan, followed by autologous peripheral blood stem cell rescue, is used to treat high-risk neuroblastoma.

Journal of Molecular Biology. 206 (4): 759–777. doi:10.1016/0022-2836(89)90583-4. PMID 2500530. Milner-White, E (1990). "Situations of gamma-turns in proteinsTheir relation to alpha-helices, beta-sheets and ligand binding sites". J. Mol. Biol. 216 (2): 385–397. doi:10.1016/S0022-2836(05)80329-8. PMID 2254936. Hutchinson, E.G.; Thornton, J.M. (1994). "A revised set of potentials for β-turn formation in proteins". Protein Science. 3 (12): 2207–2216. doi:10.1002/pro.5560031206. PMC 2142776. PMID 7756980. Pavone V, Gaeta G, Lombardi A, Nastri F, Maglio O, Isernia C, Saviano M (1996). "Discovering protein secondary structures: classification and description of isolated alpha-turns". Biopolymers. 38 (6): 705–21. doi:10.1002/(SICI)1097-0282(199606)38:6<705::AID-BIP3>3.0.CO;2-V. PMID 8652792. Rajashankar KR, Ramakumar S (1996). "Pi-turns in proteins and peptides: Classification, conformation, occurrence, hydration and sequence". Protein Sci. 5 (5): 932–46. doi:10.1002/pro.5560050515. PMC 2143406. PMID 8732765.{{cite journal}}: CS1 maint: deprecated archival service (link) Shapovalov, M; Vucetic, S; Dunbrack RL, Jr (March 2019). "A new clustering and nomenclature for beta turns derived from high-resolution protein structures". PLOS Computational Biology. 15 (3) e1006844. Bibcode:2019PLSCB..15E6844S. doi:10.1371/journal.pcbi.1006844. PMC 6424458. PMID 30845191.

The scientific Latin term octopus was derived from Ancient Greek ὀκτώπους (oktōpous), a compound form of ὀκτώ (oktō, 'eight') and πούς (pous, 'foot'), itself a variant form of ὀκτάπους, a word used for example by Alexander of Tralles (c. 525 – c. 605). The standard pluralised form of octopus in English is octopuses; the Ancient Greek plural ὀκτώποδες, octopodes (), has also been used historically. The alternative plural octopi is usually considered etymologically incorrect, because it wrongly assumes that octopus is a Latin second-declension -us noun or adjective when, in either Greek or Latin, it is a third-declension noun. Historically, the first plural to commonly appear in English language sources, in the early 19th century, is the Latinate form octopi, followed by the English form octopuses in the latter half of the same century. The Hellenic plural is roughly contemporary in usage, although it is also the rarest. A Dictionary of Modern English Usage by H. W. Fowler states that the only acceptable plural in English is octopuses, that octopi is misconceived, and octopodes pedantic; the last is nonetheless used frequently enough to be acknowledged by the descriptivist Merriam-Webster 11th Collegiate Dictionary and Webster's New World College Dictionary. The Oxford English Dictionary lists octopuses, octopi, and octopodes, in that order, reflecting frequency of use, calling octopodes rare and noting that octopi is based on a misunderstanding.

=== Tendons === Quinolones are associated with a risk of tendonitis and tendon rupture; a 2013 review found the incidence of tendon injury among those taking fluoroquinolones to be between 0.08 and 0.20%. The risk appears to be higher among people older than 60 and those also taking corticosteroids; the risk also may be higher among people who are male, have a pre-existing joint or tendon issue, have kidney disease, or are highly active. Some experts have advised avoidance of fluoroquinolones in athletes. If tendonitis occurs, it generally appears within one month, and the most common tendon injured appears to be the Achilles tendon. The cause is not well understood.

Sources: en.wikipedia.org

Reference notes

In an emergency, submarines can contact other ships to assist in rescue, and pick up the crew when they abandon ship. The crew can use escape sets such as the Submarine Escape Immersion Equipment to abandon the submarine via an escape trunk, which is a small airlock compartment that provides a route for crew to escape from a downed submarine at ambient pressure in small groups, while minimising the amount of water admitted to the submarine. The crew can avoid lung injury from over-expansion of air in the lungs due to the pressure change known as pulmonary barotrauma by maintaining an open airway and exhaling during the ascent. Following escape from a pressurized submarine, in which the air pressure is higher than atmospheric due to water ingress or other reasons, the crew is at risk of developing decompression sickness on return to surface pressure. An alternative escape means is via a deep-submergence rescue vehicle that can dock onto the disabled submarine, establish a seal around the escape hatch, and transfer personnel at the same pressure as the interior of the submarine. If the submarine has been pressurised the survivors can lock into a decompression chamber on the submarine rescue ship and transfer under pressure for safe surface decompression.

In pharmacology, relative bioavailability measures the bioavailability (estimated as the AUC) of a formulation (A) of a certain drug when compared with another formulation (B) of the same drug, usually an established standard, or through administration via a different route. When the standard consists of intravenously administered drug, this is known as absolute bioavailability (see above). F r e l = 100 ⋅ A U C A ⋅ D B A U C B ⋅ D A {\displaystyle F_{\mathrm {rel} }=100\cdot {\frac {AUC_{\mathrm {A} }\cdot D_{\mathrm {B} }}{AUC_{\mathrm {B} }\cdot D_{\mathrm {A} }}}}

Assessment — This step involves collecting data pertinent to the patient, including nutrition-related History, anthropometric Measurements, biochemical data, nutrition-focused physical findings, client history and comparative standards. Diagnosis — Based on the assessment data collected, a nutrition problem may be diagnosed. Causes and contributing factors are identified. Intervention — Based on the nutrition diagnosis, problems are addressed that aid in alleviation of the diagnosis’ signs and symptoms. Activities are constructed to enable the patient to work towards objectives set for them by themselves and their nutrition professional. Monitoring/Evaluation — Progress made on goals and/or expected outcomes is tracked to ensure that nutrition problems are being addressed; adjustments in the Intervention step are made according to progress.

Sources: en.wikipedia.org

Notes from published material

58. Dermatol Online J. 2018 May 15;24(5):13030/qt2gz9f9jk. A glimpse into the underground market of melanotan. Callaghan Iii DJ(1). Author information: (1)Department of Dermatology, Boston Medical Center, Boston, Massachusetts. danieljcallaghan3@gmail.com. Melanotan-I and melanotan-II are alpha-melanocyte stimulating hormone (a-MSH) analogues that can be purchased illicitly online with relative ease and are injected subcutaneously to stimulate a tan. Little is known about the use of these unregulated substances. An observational survey was posted to an online forum in which participants share their experiences using melanotan-I or melanotan-II. Users were asked to complete this voluntary, anonymous survey, which had questions focusing on motivation and hesitation for and against using melanotan, difficulty in acquiring it, and plans for continuing to use melanotan in the future.

The crystal lattices of solid americium and its compounds contain small intrinsic radiogenic defects due to metamictization induced by self-irradiation with alpha particles. These defects accumulate with time, which can cause a drift of some material properties and is more noticeable in older samples.

== Research == Rosiglitazone was thought to be able to benefit patients with Alzheimer's disease who do not express the ApoE4 allele, but the phase III trial designed to test this showed that rosiglitazone was ineffective in all patients, including ApoE4-negative patients. Rosiglitazone may also treat mild to moderate ulcerative colitis, due to its anti-inflammatory properties as a PPAR ligand. Rosiglitazone has been investigated as an agent that may expedite body fat redistribution into a more feminine shape in trans women who have had little fat redistribution from hormone replacement therapy, due to thiozolidinediones' effects on body fat metabolism.

On 28 March 2026 during the 2026 Iran war, a Houthi missile was launched from Yemen toward Beersheba in Southern Israel after its leader gave a speech. Hours later they confirmed launching a second missile.

Sources: pubmed.ncbi.nlm.nih.gov

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network